Merck to buy lung-disease biotech Verona Pharma for $10 billion
Merck said it will buy Verona Pharma for $10 billion to bolster its lung-disease business and help replace the expected loss of revenue once Keytruda patent protection lapses.
Related Articles
Pharmalittle: We’re reading about Trump demands on drug prices, a 340B pilot program, and much more
President Trump escalated his demands that pharma firms lower U.S. prices in line with what other countries pay, sending letters to 17 drugmakers
Pharmalittle: We’re reading about Trump demands on drug prices, a 340B pilot program, and much more
President Trump escalated his demands that pharma firms lower U.S. prices in line with what other countries pay, sending letters to 17 drugmakers
Jay Bhattacharya once studied health disparities. As NIH director, he’s allowed such research to wither
Jay Bhattacharya’s tenure as NIH director has seen health disparities research swept up in the Trump administration’s attack on DEI
Childhood vaccination rates fall again, raccoons are not friends, and more health news
The biggest health news of the day, straight to you.
Senate committee endorses NIH budget increase, rebuking Trump administration’s proposed 40% cut
Senators from both parties endorsed a $400 million increase to the budget of the National Institutes of Health on Thursday
MAGA influencers take a sudden interest in Medicare Advantage reforms, echoing a dark money group
It’s not clear why right wing influencers are suddenly pushing back against Medicare reforms.
Representatives of expert groups to be barred from work supporting CDC’s vaccine advisers
The reshaping of the CDC’s vaccine advisory panel has continued, with the apparent barring of reps of medical associations from ACIP work groups.
Lilly’s diabetes drug Mounjaro matches heart benefit of older treatment
Eli Lilly’s blockbuster diabetes drug Mounjaro matched the ability of an older treatment to prevent major heart complications in a large trial.
MAGA influencers take a sudden interest in Medicare Advantage reforms, echoing a dark money group
It’s not clear why right wing influencers are suddenly pushing back against Medicare reforms.
The U.S. needs a revolution to harness the potential of GLP-1s for weight loss
The introduction of GLP-1s for weight loss has been a dysfunctional mess, thanks to pharmaceutical companies, insurance plans, pharmacy chains, and the federal government.